← Leaderboards
Roy Ervin Strowd
Wake Forest University Health Sciences
$1,065,246
Attributed
$2,270,335
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $426.3K · FY2018–25$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,270,335 · 3
By mechanism
U24$1,253,469 · 1
R21$1,016,866 · 2
Top collaborators
- Mustapha Ahmad Ezzeddine3 shared
- Juan R Cubillos-Ruiz2 shared
- E. Alfonso Romero-Sandoval2 shared
- Aleksander Skardal2 shared
Most similar at Wake Forest University Health Sciences
Same institution · by research overlap
- Deepak Palakshappa$1,639,761
- E. Alfonso Romero-Sandoval$4,456,103
- Alain Gerald Bertoni$7,277,999
- Jeff Douglas Williamson$16,761,474
- Amber Reeves-Daniel$1,060,156
Others in their field
Other Emerging Leaders on “Research Personnel”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Joel A Lipkin · Four Points Technology, Llc$178,737,225
- Lynn Briscoe · Leidos Biomedical Research, Inc.$160,201,956
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$123,112,727
Research focus
Research PersonnelClinical ResearchDesignMultidisciplinaryTranslational ScientistTumorPharmaceutical PreparationsEffective TherapyPositioning AttributePhenotypeAlzheimer&AposResponseIn VivoBehaviorCareerGeneticCellsIn VitroMalignant NeoplasmsMechanicsReportingEthnic OriginFellowshipBaptist Church
Grant awards (7)
Wake Forest NeuroNext Clinical Site (WAKENN)$417,796
U24 · FY2025 · NS
Wake Forest NeuroNext Clinical Site (WAKENN)$409,423
U24 · FY2024 · NS
Wake Forest NeuroNext Clinical Site (WAKENN)$426,250
U24 · FY2023 · NS
IRE1a-XBP1 Signaling as a Driver of Chemotherapy-Induced Peripheral Neuropathy$185,221
R21 · FY2021 · CA
IRE1a-XBP1 Signaling as a Driver of Chemotherapy-Induced Peripheral Neuropathy$234,309
R21 · FY2020 · CA
Predicting Tumor Heterogeneity Evolution After Therapy in Patient-derived Ex Vivo Glioblastoma Organoids$294,336
R21 · FY2019 · CA
Predicting Tumor Heterogeneity Evolution After Therapy In Patient-Derived Ex Vivo Glioblastoma Organoids$303,000
R21 · FY2018 · CA